Methods: Sixty one eyes of 61 patients with macular edema secondary to branch retinal vein occlusion were evaluated retrospectively. Twenty-nine patients (group 1) received 0.7 mg single dose intravitreal dexamethasone implant and 32 patients (group 2) received 0.5 mg PRN ranibizumab injection. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline and 6 th month of injection. Both groups were compared by means of effi cieny.

Results: Group 1 received single dose intravitreal dexamethasone implant and group 2 received mean 2.38±0.87 ranibizumab injections. Mean BCVA at baseline and month 6 was 1.0828±0.60419 and 0.7566±0.53714 logarithm of the minimum angle of resolution (logMAR) in group 1; 0.9891±0.50477 and 0.5781±0.41241 logMAR in group 2, respectively. Mean CMT at baseline and month 6 was 516.48±145.890 ?m and 428.69±148.497 ?m in group 1; 535.78±106.653 ?m and 358.94±115.860 ?m in group 2, respectively. There was an increase in BCVA and reduction in CMT in both groups at month 6 (p<0.05). But CMT in group 2 was significantly less than group1 (p<0.05).

Conclusion: Both intravitreal dexamethasone implant and ranibizumab injection effi cacy was found to be similar in the treatment of macular edema secondary to branch retinal vein occlusion. However, at month 6, ranibizumab appeared to have a greater effect on central macular thickness reduction compared to intravitreal dexamethasone implant. Keywords : Branch retinal vein occlusion, dexamethasone implant, macular edema, ranibizumab